Shanghai Henlius Biotech Submits Another Application for Serplulimab in China
Shanghai Henlius Biotech Inc., (HKG: 2696) has announced a new market filing for its anti-programmed...
Shanghai Henlius Biotech Inc., (HKG: 2696) has announced a new market filing for its anti-programmed...